Novonesis to Invest €600 Million in India
The Story: Novonesis will invest €600 million to expand its Patalganga site and build an advanced enzyme production facility, expected to be operational by 2030.
The Take: The investment will boost Novonesis’ production capacity and strengthen its supply network across India, the Middle East and Africa.
India Glycols Demerges Into Three Entities
The Story: India Glycols has completed its demerger into three companies-India Glycols, IGL Spirits, and Ennature Bio Pharma-effective September 1, 2026.
The Take: The restructuring gives each business greater focus and could improve capital allocation, management oversight, and valuation clarity.
Cipla, SBP Group Partner on HER2 Bispecific ADC
The Story: Cipla has signed an exclusive deal with SBP Group’s CTTQ for TQB2102, a HER2 bispecific ADC, across India, South Africa and five emerging markets.
The Take: The deal strengthens Cipla’s oncology pipeline and expands its presence in advanced cancer therapies, subject to regulatory approvals.
